Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
Editorials & Other Articles
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Wall Street bet big against women's health company after Roe v. Wade ruling
Yahoo Finance
Wall Street bet big against women’s health company after Roe v. Wade ruling
Alexandra Semenova · Reporter
Wed, July 20, 2022 at 5:40 PM · 2 min read
Short sellers ramped up their bets against a women's contraception developer following the U.S. Supreme Court ruling last month to reverse its landmark Roe v. Wade decision, new data showed.
According to a report from S&P Global Market Intelligence published Wednesday, short interest in Evofem Biosciences (EVFM) – a pharmaceutical company that offers women reproductive and contraceptive care products – surged to over 50% in the aftermath of the ruling June 24.
Short interest in Evofem was less than 6% mid-June. Shares of Evofem initially more than doubled immediately following the Supreme Court's decision. The stock has dropped 40% from those highs; shares of Evofem are down more than 98% since the company went public in 2018.
{snip}
This year's downturn in equity markets has made 2022 a lucrative year across the board for traders betting against the stock market. U.S. equity short-sellers were up 30% for the year through the end of June, according to separate data from research firm S3 Partners.
{snip}
Wall Street bet big against women’s health company after Roe v. Wade ruling
Alexandra Semenova · Reporter
Wed, July 20, 2022 at 5:40 PM · 2 min read
Short sellers ramped up their bets against a women's contraception developer following the U.S. Supreme Court ruling last month to reverse its landmark Roe v. Wade decision, new data showed.
According to a report from S&P Global Market Intelligence published Wednesday, short interest in Evofem Biosciences (EVFM) – a pharmaceutical company that offers women reproductive and contraceptive care products – surged to over 50% in the aftermath of the ruling June 24.
Short interest in Evofem was less than 6% mid-June. Shares of Evofem initially more than doubled immediately following the Supreme Court's decision. The stock has dropped 40% from those highs; shares of Evofem are down more than 98% since the company went public in 2018.
{snip}
This year's downturn in equity markets has made 2022 a lucrative year across the board for traders betting against the stock market. U.S. equity short-sellers were up 30% for the year through the end of June, according to separate data from research firm S3 Partners.
{snip}